3589-41-1

Basic information

• Product Name: N-CARBOBENZOXYAMINOACETONITRILE
• Synonyms: Benzyl Cyanomethylcarbamate N-Cbz-aminoacetonitrile Cyanomethylcarbamic Acid Benzyl Ester;Benzyl N-(cyanomethyl)carbamate;NSC 54758;N-(Benzyloxycarbonyl)-2-aminoacetonitrile 98%;N-(Carbobenzoxy)aminoacetonitrile;N-CARBOBENZOXYAMINOACETONITRILE;N-(BENZYLOXYCARBONYL)-2-AMINOACETONITRILE;N-CBZ-AMINOACETONITRILE
• CAS NO: 3589-41-1
• Molecular Formula: C₁₀H₁₀N₂O₂
• Molecular Weight: 190.2
• Product Categories: C10 to C27;Cyanides/Nitriles;Nitrogen Compounds
• Mol File: 3589-41-1.mol
• Article Data: 28

Chemical Properties

• Melting Point: 61-63 °C(lit.)
• Boiling Point: 376.4 °C at 760 mmHg
• Flash Point: 181.5 °C
• Appearance: /
• Density: 1.181 g/cm³
• Vapor Pressure: 7.24E-06mmHg at 25°C
• Refractive Index: 1.538
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Sparingly), Methanol (Slightly)
• CAS DataBase Reference: N-CARBOBENZOXYAMINOACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: N-CARBOBENZOXYAMINOACETONITRILE(3589-41-1)
• EPA Substance Registry System: N-CARBOBENZOXYAMINOACETONITRILE(3589-41-1)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22
• Safety Statements: 36
• RIDADR: 3439
• WGK Germany: 3
• Hazardous Substances Data: 3589-41-1(Hazardous Substances Data)

Usage

General Description

N-CARBOBENZOXYAMINOACETONITRILE, also known as CBZ-GLY-NH2, is a chemical compound with the molecular formula C11H9N3O2. It is a white crystalline solid that is commonly used as an intermediate in the synthesis of various pharmaceutical compounds. N-CARBOBENZOXYAMINOACETONITRILE is often employed as a protecting group for the amino group in organic synthesis, allowing for selective reactions without affecting other functional groups. It is also utilized in the production of peptide, ester, and amine derivatives. Additionally, this compound has been studied for its potential applications in the design and development of new drugs for various medical conditions.

InChI:InChI=1/C10H10N2O2/c11-6-7-12-10(13)14-8-9-4-2-1-3-5-9/h1-5H,7-8H2,(H,12,13)

Upstream product

• 6011-14-9 2-aminoacetonitrile hydrochloride 
• 501-53-1 benzyl chloroformate 
• 540-61-4 2-aminoacetonitrile 
• 151-63-3 cyanomethylamine sulfate 
• 126714-85-0 2,3-dichlorothiophene-5-sulfonyl chloride 
• 151-63-3 aminoacetonitrile neutral sulfate 
• 75315-63-8 N-(benzyloxycarbonyl)succinimide 
• 1885-14-9 phenyl chloroformate 
• 949-90-6 N-(carbobenzyloxy)glycinamide 
• 125453-11-4 benzyl N-(1H-benzotriazol-1-ylmethyl)carbamate 
• 55378-79-5 C₁₃H₁₅NO₆ 
• 1138-80-3 N-(Benzyloxycarbonyl)glycine 

Downstream Products

• 140903-15-7 (Benzyloxycarbonylamino)thioacetimidsaeure-propylester hydrochlorid 
• 117087-87-3 2-Benzyloxycarbonylamino-acetimidic acid benzyl ester; hydrochloride 
• 161463-01-0 2-(N-benzyloxycarbonylaminomethyl)adenine 
• 63808-39-9 Benzyloxycarbonyl-imidoglycyl-L-alanin 
• 63808-40-2 Benzyloxycarbonyl-imidoglycyl-L-leucin 
• 63808-38-8 Z-ImGly-Gly-OH 
• 1755-98-2 ethyl 2-phenylmethoxycarbonylaminoethanimidate 
• 76055-02-2 2-benzyloxycarbonylamino-N-(2-pyridyl)acetamidine hydrochloride 
• 1146897-13-3 C₂₁H₂₆N₂O₄ 
• 1146897-17-7 C₂₀H₂₈N₂O₃Si 
• 1146897-15-5 C₂₀H₂₄N₂O₄ 
• 1257340-94-5 C₁₉H₁₆F₃N₃O₃ 
• 1337568-68-9 N-[(1R)-2,3,4,6-tetra-O-acetyl-1,5-anhydro-D-galactitolspiro[1.4]-2-benzyloxycarbonylaminomethyl-2-oxazolin-5-ylidene]glycine methylester 
• 1337568-74-7 N-(2,3,4,6-tetra-O-acetyl-1-deoxy-1-Z-glycylamido-β-D-galactopyranosylcarbonyl)glycine methylester 

Relevant articles and documents

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.